Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


  1. Fuerst, Mark L.


In the upfront treatment of multiple myeloma, the addition of triple therapy with bortezomib, lenalidomide, and dexamethasone (RVD) for consolidation or a second autologous hematopoietic cell transplant is not superior to a single transplant followed by lenalidomide maintenance, according to the largest randomized controlled trial of post-transplant therapy for multiple myeloma ever conducted in the U.S.